Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy

(2018) Guillaume Herbreteau et al.   Oncotarget

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

(2018) Carl Morrison et al.   Journal for ImmunoTherapy of Cancer

Mutation load estimation model as a predictor of the response to cancer immunotherapy

(2018) Guan-Yi Lyu et al.   npj Genomic Medicine

Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis

(2018) Ivo Buchhalter et al.   INTERNATIONAL JOURNAL OF CANCER

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting

(2018) Steven P. Rowe et al.   Molecular Oncology

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity

(2018) Weiwei Shi et al.   Cell Reports

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

(2017) Ferdinand Seith et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma

(2017) Jenny H. J. Lee et al.   Pigment Cell & Melanoma Research

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma

(2017) Tara C. Gangadhar et al.   Pigment Cell & Melanoma Research

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

(2017) Whijae Roh et al.   Science Translational Medicine

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

The role of neoantigens in response to immune checkpoint blockade

(2016) Nadeem Riaz et al.   INTERNATIONAL IMMUNOLOGY

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma

(2016) Dakai Xiao et al.   Oncotarget

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Gender Disparity and Mutation Burden in Metastatic Melanoma

(2015) Sameer Gupta et al.   JNCI-Journal of the National Cancer Institute

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Gender Disparity and Mutation Burden in Metastatic Melanoma

(2015) Sameer Gupta et al.   JNCI-Journal of the National Cancer Institute

Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer

(2014) Karen-Lise Garm Spindler et al.   INTERNATIONAL JOURNAL OF CANCER

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis

(2014) Simon J. Furney et al.   Pigment Cell & Melanoma Research

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments

(2013) J. F. Huggett et al.   CLINICAL CHEMISTRY

Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma

(2013) Simon J Furney et al.   JOURNAL OF PATHOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER